4//SEC Filing
VAMVAKAS ELIAS 4
Accession 0001493152-20-013071
CIK 0001299139other
Filed
Jul 9, 8:00 PM ET
Accepted
Jul 10, 12:57 PM ET
Size
9.2 KB
Accession
0001493152-20-013071
Insider Transaction Report
Form 4
TearLab CorpTEAR
VAMVAKAS ELIAS
Director
Transactions
- Disposition from Tender
Common Stock
2020-07-09$0.06/sh−130,813$7,666→ 0 total(indirect: See footnote) - Disposition from Tender
Common Stock
2020-07-09$0.06/sh−20,140$1,180→ 0 total - Disposition from Tender
Common Stock
2020-07-09$0.06/sh−32,000$1,875→ 0 total(indirect: See footnote)
Footnotes (3)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated May 11, 2020 (the "Merger Agreement"), among Accelmed Partners II LP, a Cayman Islands exempted limited partnership ("Buyer"), the Issuer and Accelmed Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Buyer, each issued and outstanding share of Issuer common stock and preferred stock (other than Cancelled Shares (as defined in the Merger Agreement)) was cancelled and automatically converted into the right to receive an amount equal to $0.0586 per share in cash, without interest and less any required withholding taxes, effective at the time of the Merger (as defined in the Merger Agreement).
- [F2]Shares held by Greybrook Capital, Inc. The reporting person is an officer and a director of Greybrook Capital Inc. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]Shares held by Greybrook Corporation. The reporting person is an officer and a director of Greybrook Corporation. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Documents
Issuer
TearLab Corp
CIK 0001299139
Entity typeother
Related Parties
1- filerCIK 0001061865
Filing Metadata
- Form type
- 4
- Filed
- Jul 9, 8:00 PM ET
- Accepted
- Jul 10, 12:57 PM ET
- Size
- 9.2 KB